Phathom Pharmaceuticals (PHAT)
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United Sta...
- Open
- 9.330
- High
- 9.745
- Low
- 9.175
- Prev. Close
- 9.280
- Volume
- 976.46K
- Turnover
- 9.13M
- Avg Price
- 9.354
- Bid/Ask Ratio
- -75.44%
- Amplitude
- 6.14%
- 52wk High
- 18.310
- Volume Ratio
- 0.79
- Turnover Ratio
- 1.63%
Phathom Pharmaceuticals Analyst Rating
View moreForecast & Rating
Aug 14, 2026Price forecast
$21.50132.43%
Forecast & RatingStrong buy
11analysts
- Strong buy72.73%
- Buy18.18%
- Hold9.09%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Aug 11 at 04:13 AM
Hennion & Walsh Asset Management Inc. Has $3.55 Million Stake in Phathom Pharmaceuticals, Inc. $PHAT
- Market Beat · Aug 4 at 12:00 PM
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 5.5% - Here's Why
- prnewswire · Jul 30 at 04:35 PM
17:34 ETPhathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT)
- Quartr · Jul 30 at 06:21 AM
PHAT: VOQUEZNA drives GI market innovation with strong growth, clinical success, and extended exclusivity
- Earnings Watch · Jul 30 at 06:07 AM
Phathom Pharmaceuticals | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 74.27 M
- PUBT · Jul 30 at 06:01 AM
Phathom Q2 GAAP net loss narrows to $17.6 million from year-ago; revenue rises 88% to $74.3 million
